|The Netherlands Cancer Institute
WHO is the trial for?
WHAT is the key question that this trial is attempting to answer?
|This study aims to better understand, how the preoperative radiotherapy for sarcoma patients might be simplified by reducing the number of treatment sessions to 14 in 3 weeks instead of 25 sessions in 5 weeks. Toxicity of the two regimens and wound complications will be assessed.
WHY patients might want to participate?
|This clinical trial offers patients an opportunity to access a new therapy strategy with potentially less side effects. It will further support the research in sarcomas and potentially help other patients with this disease. For more about the importance and benefits of joining clinical trials, please here.
WHEN will the trial be open?
|The study is open/recruiting.
WHERE is the trial available?
|The trial is available in several study centers in The Netherlands. For further information please check here.
STUDY DESIGN: What does the study look like?
|The study has two arms: One group will receive the conventionally fractionated regimen of 25 x 2 Gy in five weeks, the other group will receive a shorter preoperative regimen of 14 x 3 Gy.
HOW do I get more information?
|Patient organisations supporting GIST and/or sarcoma patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organisations serving GIST and/or sarcoma patients. If there are no such organisation in your country, please email us for more information: firstname.lastname@example.org
SHARE your experience
|You want to share your experience on this trial?
Send us an e-mail to: email@example.com
Note that your experience would be helpful for other patients and patient organisations.
RESULTS of the study
|No results are available at this time. Future results will be linked here.
Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.